Ruth O'Regan, MD, University of Rochester Medical Center

home / authors / ruth-o-regan-md-university-of-rochester-medical-center

Articles

Ruth M. O’Regan, MD

Dr. O’Regan on the Development of Oral SERDs in Breast Cancer

Ruth O'Regan, MD, University of Rochester Medical Center
August 9th 2022

Ruth M. O’Regan, MD, discusses the development of oral selective estrogen receptor degraders in hormone receptor–positive breast cancer.

Read More

Updated Data for Metastatic HER2+ Breast Cancer

Updated Data for Metastatic HER2+ Breast Cancer

Ruth O'Regan, MD, University of Rochester Medical Center;Joyce O'Shaugnessy, MD, Texas Oncology;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Debu Tripathy, MD, MD Anderson Cancer Center
January 25th 2021

Read More

Prognostic Tools for Early-Stage HER2+ Breast Cancer

Prognostic Tools for Early-Stage HER2+ Breast Cancer

Ruth O'Regan, MD, University of Rochester Medical Center;Joyce O'Shaugnessy, MD, Texas Oncology;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Debu Tripathy, MD, MD Anderson Cancer Center
January 25th 2021

Read More

Current Treatment Landscape for HER2+ Breast Cancer

Current Treatment Landscape for HER2+ Breast Cancer

Ruth O'Regan, MD, University of Rochester Medical Center;Joyce O'Shaugnessy, MD, Texas Oncology;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Debu Tripathy, MD, MD Anderson Cancer Center
January 25th 2021

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need